ACURA PHARMACEUTICALS, INC. Announces Definitive Agreement and Acquisition
| Field | Detail |
|---|---|
| Company | Acura Pharmaceuticals, Inc |
| Form Type | 8-K |
| Filed Date | May 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: definitive-agreement, acquisition, financial-obligation
TL;DR
ACURA PHARMACEUTICALS, INC. just signed a big deal and bought something. Details to follow.
AI Summary
On May 29, 2025, ACURA PHARMACEUTICALS, INC. entered into a material definitive agreement and completed an acquisition. The company also incurred a direct financial obligation. Specific details regarding the agreement, acquisition, and financial obligation are not fully disclosed in this filing.
Why It Matters
This filing indicates significant corporate activity for ACURA PHARMACEUTICALS, INC., including a new agreement and an acquisition, which could impact its future business operations and financial standing.
Risk Assessment
Risk Level: medium — The filing indicates material definitive agreements and completion of an acquisition, which inherently carry financial and operational risks.
Key Players & Entities
- ACURA PHARMACEUTICALS, INC. (company) — Registrant
- May 29, 2025 (date) — Date of earliest event reported
- New York (jurisdiction) — State of incorporation
- 1-10113 (identifier) — Commission File Number
- 11-0853640 (identifier) — I.R.S. Employer Identification Number
- 616 N. North Court, Suite 120 (address) — Business and Mail Address
- Palatine, IL 60067 (address) — City, State, Zip
- HALSEY DRUG CO INC/NEW (company) — Former Company Name
- 19920703 (date) — Date of former company name change
FAQ
What is the nature of the material definitive agreement entered into by ACURA PHARMACEUTICALS, INC. on May 29, 2025?
The filing indicates the entry into a material definitive agreement, but the specific terms and counterparty are not detailed in the provided text.
What was acquired or disposed of in the completion of an acquisition or disposition of assets by ACURA PHARMACEUTICALS, INC.?
The filing states the completion of an acquisition or disposition of assets, but the specific assets or entities involved are not disclosed in the provided text.
What is the nature of the direct financial obligation or off-balance sheet arrangement incurred by ACURA PHARMACEUTICALS, INC.?
The filing mentions the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the details of this obligation are not provided.
When was ACURA PHARMACEUTICALS, INC. incorporated or organized?
ACURA PHARMACEUTICALS, INC. was incorporated or organized in New York.
What is the business address of ACURA PHARMACEUTICALS, INC.?
The business address of ACURA PHARMACEUTICALS, INC. is 616 N. North Court, Suite 120, Palatine, IL 60067.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 30, 2025 regarding ACURA PHARMACEUTICALS, INC.